Home/Filings/4/0001209191-23-047454
4//SEC Filing

Wertheimer Samuel P 4

Accession 0001209191-23-047454

CIK 0001814140other

Filed

Aug 24, 8:00 PM ET

Accepted

Aug 25, 7:39 PM ET

Size

12.7 KB

Accession

0001209191-23-047454

Insider Transaction Report

Form 4
Period: 2023-08-23
Wertheimer Samuel P
DirectorChief Executive Officer
Transactions
  • Disposition to Issuer

    Warrants (right to buy)

    2023-08-231,8450 total
    Exercise: $1.75Exp: 2028-08-21Common Stock (1,845 underlying)
  • Disposition to Issuer

    Warrants (right to buy)

    2023-08-2312,3830 total
    Exercise: $11.50Exp: 2027-07-29Common Stock (12,383 underlying)
  • Disposition to Issuer

    Common Stock

    2023-08-23146,3830 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2023-08-23100,0000 total
    Exercise: $2.65Exp: 2032-09-29Common Stock (100,000 underlying)
Footnotes (4)
  • [F1]Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share.
  • [F2]The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
  • [F3]The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 2,136 shares of Pyxis common stock at an exercise price of $66.67 per share.
  • [F4]The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 318 shares of Pyxis common stock at an exercise price of $10.15 per share.

Issuer

Apexigen, Inc.

CIK 0001814140

Entity typeother

Related Parties

1
  • filerCIK 0001293250

Filing Metadata

Form type
4
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 7:39 PM ET
Size
12.7 KB